Suppr超能文献

德语国家胆碱能性荨麻疹患者的疾病影响、诊断延迟及未满足的医疗需求

Disease Impact, Diagnostic Delay, and Unmet Medical Needs of Patients With Cholinergic Urticaria in German-Speaking Countries.

作者信息

Altrichter Sabine, Mellerowicz Emilia, Terhorst-Molawi Dorothea, Grekowitz Eva, Weller Karsten, Maurer Marcus

机构信息

Institute for Allergology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universitätzu Berlin, Berlin, Germany.

Department of Dermatology and Venerology, Kepler University Hospital, Linz, Austria.

出版信息

Front Allergy. 2022 May 25;3:867227. doi: 10.3389/falgy.2022.867227. eCollection 2022.

Abstract

BACKGROUND

Cholinergic urticaria (CholU) is a common type of chronic inducible urticaria. Little is known about the burden of the disease and its unmet medical needs.

AIM

To characterize the unmet medical needs of patients with CholU.

METHODS

Patients with CholU ( = 111) took part in a German online survey that assessed their symptoms, diagnostic delay, impact on daily life, quality of life (QoL), and their experience with physician care.

RESULTS

Virtually all patients reported typical signs and symptoms of CholU, i.e., whealing (93.7%) and itching (91.9%), in response to typical trigger situations, such as physical activity, passive warming, or stress. Despite this, patients reported a marked diagnostic delay of 30.2 months (range from 0 to 279 months). Only 38% of the patients received a blood examination, and only 16% underwent provocation testing for diagnosing CholU, as recommended by the international guidelines. Physician contacts were common, but patient satisfaction with their disease management was low. In total, 90.1% of the patients stated to have an uncontrolled disease, resulting in a strong impact on their everyday activities, sleep, and QoL.

CONCLUSION

Patients with CholU exhibit many important unmet needs, and improvement in the diagnostic workup and patient care is needed, as are better treatment options.

摘要

背景

胆碱能性荨麻疹(CholU)是慢性诱导性荨麻疹的一种常见类型。关于该疾病的负担及其未满足的医疗需求,人们了解甚少。

目的

描述胆碱能性荨麻疹患者未满足的医疗需求。

方法

111名胆碱能性荨麻疹患者参与了一项德国在线调查,该调查评估了他们的症状、诊断延迟、对日常生活的影响、生活质量(QoL)以及他们接受医生治疗的经历。

结果

几乎所有患者都报告了胆碱能性荨麻疹的典型体征和症状,即对典型触发情况(如体育活动、被动升温或压力)出现风团(93.7%)和瘙痒(91.9%)。尽管如此,患者报告诊断明显延迟30.2个月(范围从0至279个月)。只有38%的患者接受了血液检查,只有16%的患者按照国际指南的建议进行了激发试验以诊断胆碱能性荨麻疹。患者与医生的接触很常见,但患者对疾病管理的满意度较低。总体而言,90.1%的患者表示疾病未得到控制,这对他们的日常活动、睡眠和生活质量产生了强烈影响。

结论

胆碱能性荨麻疹患者存在许多重要的未满足需求,需要改进诊断检查和患者护理,也需要更好的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9de9/9234879/594c466c80e9/falgy-03-867227-g0001.jpg

相似文献

1
Disease Impact, Diagnostic Delay, and Unmet Medical Needs of Patients With Cholinergic Urticaria in German-Speaking Countries.
Front Allergy. 2022 May 25;3:867227. doi: 10.3389/falgy.2022.867227. eCollection 2022.
3
Development and validation of the Cholinergic Urticaria Quality-of-Life Questionnaire (CholU-QoL).
Clin Exp Allergy. 2018 Apr;48(4):433-444. doi: 10.1111/cea.13102. Epub 2018 Feb 28.
4
Real-life treatment of patients with cholinergic urticaria in German-speaking countries.
J Dtsch Dermatol Ges. 2019 Nov;17(11):1141-1147. doi: 10.1111/ddg.13979.
5
Cholinergic Urticaria: Subtype Classification and Clinical Approach.
Am J Clin Dermatol. 2023 Jan;24(1):41-54. doi: 10.1007/s40257-022-00728-6. Epub 2022 Sep 15.
6
Atopic predisposition in cholinergic urticaria patients and its implications.
J Eur Acad Dermatol Venereol. 2016 Dec;30(12):2060-2065. doi: 10.1111/jdv.13765. Epub 2016 Jun 21.
7
Acetylcholine-induced whealing in cholinergic urticaria - What does it tell us?
J Dermatol Sci. 2021 Jul;103(1):10-15. doi: 10.1016/j.jdermsci.2021.05.001. Epub 2021 May 7.
9
Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria.
J Dermatol Sci. 2014 Aug;75(2):88-93. doi: 10.1016/j.jdermsci.2014.04.007. Epub 2014 May 1.
10
Cholinergic Urticaria: Clinical Presentation and Natural History in a Tropical Country.
Biomed Res Int. 2020 May 24;2020:7301652. doi: 10.1155/2020/7301652. eCollection 2020.

本文引用的文献

1
An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
J Allergy Clin Immunol. 2022 May;149(5):1683-1690.e7. doi: 10.1016/j.jaci.2021.12.772. Epub 2021 Dec 23.
2
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease.
Nat Rev Drug Discov. 2022 Jan;21(1):21-40. doi: 10.1038/s41573-021-00266-6. Epub 2021 Aug 20.
3
Biologics for the Use in Chronic Spontaneous Urticaria: When and Which.
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1067-1078. doi: 10.1016/j.jaip.2020.11.043.
5
Cholinergic Urticaria: Clinical Presentation and Natural History in a Tropical Country.
Biomed Res Int. 2020 May 24;2020:7301652. doi: 10.1155/2020/7301652. eCollection 2020.
6
Real-life treatment of patients with cholinergic urticaria in German-speaking countries.
J Dtsch Dermatol Ges. 2019 Nov;17(11):1141-1147. doi: 10.1111/ddg.13979.
7
Ligelizumab for Chronic Spontaneous Urticaria.
N Engl J Med. 2019 Oct 3;381(14):1321-1332. doi: 10.1056/NEJMoa1900408.
8
Angioedema frequently occurs in cholinergic urticaria.
J Allergy Clin Immunol Pract. 2019 Apr;7(4):1355-1357.e1. doi: 10.1016/j.jaip.2018.10.013. Epub 2018 Oct 25.
9
Real-life treatment of cholinergic urticaria with omalizumab.
J Allergy Clin Immunol. 2019 Feb;143(2):788-791.e8. doi: 10.1016/j.jaci.2018.08.050. Epub 2018 Oct 9.
10
How to Approach Chronic Inducible Urticaria.
J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1119-1130. doi: 10.1016/j.jaip.2018.03.007.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验